Synergy Pharmaceuticals to Present at the Canaccord Genuity Growth Conference

NEW YORK--(BUSINESS WIRE)--

Synergy Pharmaceuticals Inc. SGYP today announced that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Canaccord Genuity 35^th Annual Growth Conference on Thursday, August 13^th, 2015 at 11:30 a.m. Eastern Time at the InterContinental in Boston, Massachusetts.

A live webcast of the presentation will be accessible through the Investor Relations section of the company's website at www.synergypharma.com. A replay of the webcast will be available on Synergy's website for 60 days following the conference.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of novel therapies for the treatment of gastrointestinal (GI) diseases and disorders. Synergy's proprietary GI platform is based on uroguanylin, a naturally occurring human peptide and key regulator of normal GI activity. Plecanatide is our lead uroguanylin analogue currently in late-stage clinical development for chronic idiopathic constipation and irritable bowel syndrome with constipation. Dolcanatide (SP-333) is our next-generation uroguanylin analogue presently being explored for ulcerative colitis. For more information, please visit www.synergypharma.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150804005365/en/